Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
Get Alerts PTGX Hot Sheet
Join SI Premium – FREE
Presentation Details:
Date:
Time:
Location: New York
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 stage of development. The REVIVE study is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains all worldwide development and commercialization rights to rusfertide.
Positive topline results from the FRONTIER 1 study of JNJ-2113 in moderate-to-severe plaque psoriasis became available in
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at protagonist-inc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jmp-securities-life-sciences-conference-301822673.html
SOURCE Protagonist Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SK hynix Announces 1Q24 Financial Results
- Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada
- NB Bancorp, Inc. Reports First Quarter 2024 Financial Results
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!